ImmuPharma plc (LON:IMM – Get Free Report)’s stock price shot up 18.3% on Friday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.26 ($0.05). 26,333,650 shares traded hands during trading, an increase of 36% from the average session volume of 19,375,852 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Performance
The firm has a 50 day moving average of GBX 1.71 and a 200-day moving average of GBX 1.72. The stock has a market capitalization of £16.39 million, a PE ratio of -393.60 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What Are Some of the Best Large-Cap Stocks to Buy?
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- How to Use the MarketBeat Stock Screener
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What is the Nasdaq? Complete Overview with History
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
